In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: Predictability of in vivo interactions

Basic and Clinical Pharmacology and Toxicology

Volumn 103, Issue 2, 2008, Pages 157-165

  Karjalainen, Marjo J ^a   Neuvonen, Pertti J ^a   Backman, Janne T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CIPROFLOXACIN; CYTOCHROME P450 1A2; DESOGESTREL; ETHINYLESTRADIOL; ETODOLAC; ETORICOXIB; FLUVOXAMINE; GESTODENE; MEFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENACETIN; PROGESTERONE; ROFECOXIB; SEX HORMONE; TIZANIDINE; TOLFENAMIC ACID; ZOLMITRIPTAN;

AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CONTRACEPTIVE AGENTS, FEMALE; CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MICROSOMES, LIVER; PREDICTIVE VALUE OF TESTS;

EID: 47649091430     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00252.x     Document Type: Article

References (61)

1. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005 97 : 125 34.
2. Rasmussen BB, Brix TH, Kyvik KO, Brøsen K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002 12 : 473 8.
3. Korhonen LE, Rahnasto M, Mahonen NJ, Wittekindt C, Poso A, Juvonen RO et al. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem 2005 48 : 3808 15.
4. Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 1991 19 : 561 7.
5. Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995 50 : 205 11.
6. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 2004 57 : 349 53.
7. Wild MJ, McKillop D, Butters CJ. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica 1999 29 : 847 57.
8. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985 260 : 9057 67.
9. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994 38 : 471 3.
10. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993 45 : 1211 4.
11. Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992 36 : 942 8.
12. Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 1993 6 : 649 56.
13. Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 2004 75 : 331 41.
14. Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, Neuvonen PJ. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 2006 62 : 345 57.
15. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004 76 : 598 606.
16. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005 78 : 400 11.
17. Karjalainen MJ, Neuvonen PJ, Backman JT. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. Drug Metab Dispos 2006 34 : 2091 6.
18. Karjalainen MJ, Neuvonen PJ, Backman JT. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. Eur J Clin Pharmacol 2007 63 : 829 36.
19. Bachmann KA. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 2006 7 : 1 14.
20. Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002 91 : 1923 35.
21. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J et al. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS Pharm Sci 2002 4 : article 25.
22. Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004 57 : 473 86.
23. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006 316 : 336 48.
24. Brown HS, Galetin A, Hallifax D, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006 45 : 1035 50.
25. Pelkonen O, Turpeinen M, Uusitalo J, Rautio A, Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin Pharmacol Toxicol 2005 96 : 167 75.
26. Brown HS, Ito K, Galetin A, Houston JB. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005 60 : 508 18.
27. Tornheim K. Kinetic applications using high substrate and competitive inhibitor concentrations to determine Ki or Km. Anal Biochem 1994 221 : 53 6.
28. Madan A, Usuki E, Burton L, Ogilvie B, Parkinson A. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In : Rodrigues AD (ed.). Drug-Drug Interactions. Merkel Dekker Inc., West Point, NY, 2002 217 94.
29. Karjalainen MJ, Neuvonen PJ, Backman JT. Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. Eur J Clin Pharmacol 2008 64 : 511 9.
30. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003 31 : 815 32.
31. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC et al. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993 265 : 401 7.
32. Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos 1990 18 : 1005 10.
33. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996 51 : 73 8.
34. Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I et al. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 2001 70 : 415 24.
35. Harder S, Fuhr U, Staib AH, Wolff T. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 1989 87 : 89S 91S.
36. Grime K, Riley RJ. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 2006 7 : 251 64.
37. Regmi NL, Abd El-Aty AM, Kuroha M, Nakamura M, Shimoda M. Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs. J Vet Pharmacol Ther 2005 28 : 553 7.
38. Fuhr U, Strobl G, Manaut F, Anders EM, Sorgel F, Lopez-de-Brinas E et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993 43 : 191 9.
39. Roberts RK, Grice J, McGuffie C, Heilbronn L. Oral contraceptive steroids impair the elimination of theophylline. J Lab Clin Med 1983 101 : 821 5.
40. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985 28 : 425 8.
41. Helton ED, Goldzieher JW. Metabolism of ethynyl estrogens. J Toxicol Environ Health 1977 3 : 231 41.
42. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z et al. Pharmacokinetic drug interactions involving 17alpha- ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007 46 : 133 57.
43. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006 34 : 191 7.
44. Gentile DM, Verhoeven CH, Shimada T, Back DJ. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 1998 287 : 975 82.
45. Pentikäinen PJ, Neuvonen PJ, Backman C. Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol 1981 19 : 359 65.
46. Dollery C. Therapeutic Drugs, 2nd edn. Churchill Livingstone, Edinburgh, UK, 1999.
47. FDA Celebrex (Celecoxib) Capsules Application No.: 21-156 & 20998/S007 Clinical Pharmacology Biopharmaceutics reviews section. 1999. URL: http://www.fda.gov/CDER/foi/nda/99/21156-S007_Celebrex.htm
48. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003 74 : 130 7.
49. EMEA Celecoxib BILAG I PRODUKTRESUME. 2006. URL: http://www.emea.europa. eu/humandocs/PDFs/EPAR/onsenal/H-466-PI-da.pdf
50. Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE et al. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001 29 : 813 20.
51. Schwartz JI, Agrawal NG, Hartford AH, Cote J, Hunt TL, Verbesselt R et al. The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin. J Clin Pharmacol 2007 47 : 620 7.
52. Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother 1983 23 : 559 64.
53. Neuvonen PJ, Kivistö KT. Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. Eur J Clin Pharmacol 1988 35 : 495 501.
54. Merck & Co. Inc. VIOXX (rofecoxib tablets and oral suspension). 2002. URL: http://www.merck.com/product/usa/pi_circulars/v/vioxx/vioxx_pi.pdf
55. Agrawal NG, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ et al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003 43 : 268 76.
56. Agrawal NG, Matthews CZ, Mazenko RS, Kline WF, Woolf EJ, Porras AG et al. Pharmacokinetics of etoricoxib in patients with renal impairment. J Clin Pharmacol 2004 44 : 48 58.
57. Dixon R, Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997 18 : 15 20.
58. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005 72 : 168 74.
59. Kuhnz W, Pfeffer M, al-Yacoub G. Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum. J Steroid Biochem 1990 35 : 313 8.
60. Stanczyk FZ. Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism. Contraception 1997 55 : 273 82.
61. Kuhl H, Jung-Hoffmann C, Heidt F. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene. Contraception 1988 38 : 477 86.